- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
63matching registry records
Matching recruiting site observations50
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 / AMAZE 5 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3400 estimated | 1 matching recruitingPhoenix, Arizona, 85053, United States | Aug 14, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07481630 ↗ |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 1 matching recruitingGlendale, Arizona, 85304, United States | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 / AMAZE 4 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 1 matching recruitingGilbert, Arizona, 85297, United States | Jun 26, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571109 ↗ |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 32,500 estimated | 2 matching recruitingGilbert, Arizona, 85296, United States / Phoenix, Arizona, 85006, United States | Feb 23, 2028estimated | Jul 8, 2026ClinicalTrials.gov | Open NCT07564414 ↗ |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 21,481 estimated | 3 matching recruitingChandler, Arizona, 85225, United States / Scottsdale, Arizona, 85260, United States / Tucson, Arizona, 85712, United States | Sep 2027estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06143956 ↗ |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 2200 estimated | 3 matching recruitingGilbert, Arizona, 85296, United States / Phoenix, Arizona, 85020, United States / Tucson, Arizona, 85741, United States | Mar 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07215559 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 / ENLIGHTEN-2 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,035 estimated | 1 matching recruitingTucson, Arizona, 85712, United States | Jan 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07282600 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,980 estimated | 1 matching recruitingScottsdale, Arizona, 85260, United States | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07321886 ↗ |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 / ENLIGHTEN-4 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 3 matching recruitingMesa, Arizona, 85206, United States / Mesa, Arizona, 85209, United States / Tucson, Arizona, 85712, United States | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07353931 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 3 matching recruitingPhoenix, Arizona, 85016, United States / Scottsdale, Arizona, 85260, United States / Tucson, Arizona, 85741, United States | Jun 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07392190 ↗ |
| A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608 / Eli Lilly and Company | RecruitingVerified 2026-06 | Phase 2400 estimated | 3 matching recruitingChandler, Arizona, 85225, United States / Scottsdale, Arizona, 85260, United States / Tucson, Arizona, 85712, United States | Sep 2027estimated | Jun 24, 2026ClinicalTrials.gov | Open NCT07589608 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 / Enith1 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 32,000 estimated | 1 matching recruitingTucson, Arizona, 85711, United States | Jul 24, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351045 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 / Enith2 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 31,600 estimated | 1 matching recruitingTucson, Arizona, 85711, United States | Aug 7, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351058 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 2 matching recruitingPhoenix, Arizona, 85020, United States / Phoenix, Arizona, 85044, United States | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 4 matching recruitingPhoenix, Arizona, 85006, United States / Phoenix, Arizona, 85044, United States / Tucson, Arizona, 85704, United States / 1 more area | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 / Amgen | RecruitingVerified 2026-06 | Phase 2180 estimated | 3 matching recruitingChandler, Arizona, 85224, United States / Phoenix, Arizona, 85044, United States / Tucson, Arizona, 85715, United States | Sep 29, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07441252 ↗ |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 / Amgen | RecruitingVerified 2026-07 | Phase 3300 estimated | 2 matching recruitingChandler, Arizona, 85224, United States / Sun City, Arizona, 85351, United States | Jan 3, 2028estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07575399 ↗ |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 / Altimmune, Inc. | RecruitingVerified 2026-03 | Phase 2100 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 31, 2027estimated | Mar 20, 2026ClinicalTrials.gov | Open NCT07009860 ↗ |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 6 matching recruitingChandler, Arizona, 85224, United States / Gilbert, Arizona, 85297, United States / Peoria, Arizona, 85381, United States / 3 more areas | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 5 matching recruitingPeoria, Arizona, 85381, United States / Scottsdale, Arizona, 85258, United States / Tucson, Arizona, 85712, United States / 1 more area | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,590 estimated | 4 matching recruitingPeoria, Arizona, 85381, United States / Scottsdale, Arizona, 85258, United States / Tucson, Arizona, 85712, United States / 1 more area | Jun 5, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632457 ↗ |
| A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07553299 / Verdiva Bio Dev Limited | Not yet recruitingVerified 2026-06 | Phase 2120 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 30, 2026estimated | Jun 3, 2026ClinicalTrials.gov | Open NCT07553299 ↗ |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 37,101 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 1, 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT05669755 ↗ |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 / RENEW 2 / Novo Nordisk A/S | Active, not recruitingVerified 2026-04 | Phase 3330 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 12, 2027estimated | Apr 21, 2026ClinicalTrials.gov | Open NCT07220759 ↗ |
| A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 150 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 3, 2026estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07605052 ↗ |
| A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07281937 / EVOLVE-2 / Verdiva Bio Dev Limited | Active, not recruitingVerified 2026-06 | Phase 2206 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 2026estimated | Jun 3, 2026ClinicalTrials.gov | Open NCT07281937 ↗ |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 2367 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06603571 ↗ |
| A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 / Carmot Therapeutics, Inc. | Active, not recruitingVerified 2026-06 | Phase 2447 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 29, 2026actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06628362 ↗ |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 / MARITIME-1 / Amgen | Active, not recruitingVerified 2025-10 | Phase 33,853 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 21, 2027estimated | Oct 20, 2025ClinicalTrials.gov | Open NCT06858839 ↗ |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 / MARITIME-2 / Amgen | Active, not recruitingVerified 2025-12 | Phase 31,105 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 21, 2027estimated | Dec 31, 2025ClinicalTrials.gov | Open NCT06858878 ↗ |
| Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 / Zealand Pharma | Active, not recruitingVerified 2026-01 | Phase 2221 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 13, 2026estimated | Jan 15, 2026ClinicalTrials.gov | Open NCT06926842 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 / TRIUMPH-3 / Eli Lilly and Company | Active, not recruitingVerified 2026-05 | Phase 31,946 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 16, 2026actual | May 22, 2026ClinicalTrials.gov | Open NCT05882045 ↗ |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3320 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06297603 ↗ |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 310,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 2029estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06383390 ↗ |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 / TRIUMPH-5 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3800 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06662383 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 / TRIUMPH-7 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3586 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 2027estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07035093 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 / TRIUMPH-9 / Eli Lilly and Company | Active, not recruitingVerified 2026-06 | Phase 3600 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 2028estimated | Jun 9, 2026ClinicalTrials.gov | Open NCT07357415 ↗ |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2026-04 | Phase 31,100 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2027estimated | Apr 7, 2026ClinicalTrials.gov | Open NCT07104383 ↗ |
| VK2735 for Weight Management Phase 3NCT07104500 / VANQUISH 1 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2025-11 | Phase 34,500 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2027estimated | Nov 24, 2025ClinicalTrials.gov | Open NCT07104500 ↗ |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 2698 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 17, 2024actual | Nov 19, 2025ClinicalTrials.gov | Open NCT05016882 ↗ |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 32,734 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 19, 2025actual | Jul 8, 2026ClinicalTrials.gov | Open NCT06065540 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 / Novo Nordisk A/S | CompletedVerified 2026-04 | Phase 31,024 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 4, 2026actual | Apr 22, 2026ClinicalTrials.gov | Open NCT06221969 ↗ |
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2270 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 21, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06409130 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 / REIMAGINE 5 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 31,023 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 2, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06534411 ↗ |
| A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06230523 / Eli Lilly and Company | CompletedVerified 2026-05Registry results posted | Phase 2263 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 30, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06230523 ↗ |
| A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT06525935 / Carmot Therapeutics, Inc. | CompletedVerified 2026-04 | Phase 2469 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 8, 2025actual | Apr 17, 2026ClinicalTrials.gov | Open NCT06525935 ↗ |
| Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusNCT05669599 / Amgen | CompletedVerified 2026-01 | Phase 2592 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 8, 2024actual | Jan 20, 2026ClinicalTrials.gov | Open NCT05669599 ↗ |
| A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807 / Eli Lilly and Company | CompletedVerified 2026-03Registry results posted | Phase 2179 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 22, 2025actual | Apr 21, 2026ClinicalTrials.gov | Open NCT06124807 ↗ |
| A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderNCT06817356 / Eli Lilly and Company | CompletedVerified 2026-07 | Phase 2308 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 19, 2026actual | Jul 16, 2026ClinicalTrials.gov | Open NCT06817356 ↗ |
| ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885 / Altimmune, Inc. | CompletedVerified 2023-07 | Phase 195 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 17, 2022actual | Jul 27, 2023ClinicalTrials.gov | Open NCT05006885 ↗ |
| Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 / Altimmune, Inc. | CompletedVerified 2023-11 | Phase 2391 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 28, 2023actual | Nov 29, 2023ClinicalTrials.gov | Open NCT05295875 ↗ |
| IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711 / IMPACT / Altimmune, Inc. | CompletedVerified 2026-05 | Phase 2212 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 25, 2025actual | May 18, 2026ClinicalTrials.gov | Open NCT05989711 ↗ |
| A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760 / Eli Lilly and Company | CompletedVerified 2023-08Registry results posted | Phase 2338 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 16, 2022actual | Sep 13, 2023ClinicalTrials.gov | Open NCT04881760 ↗ |
| A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 / Eli Lilly and Company | CompletedVerified 2025-04 | Phase 143 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2, 2025actual | Apr 18, 2025ClinicalTrials.gov | Open NCT05916560 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 / TRIUMPH-1 / Eli Lilly and Company | CompletedVerified 2026-06 | Phase 32,335 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 6, 2026actual | Jun 3, 2026ClinicalTrials.gov | Open NCT05929066 ↗ |
| A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 / TRIUMPH-4 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 3445 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 14, 2025actual | Jan 21, 2026ClinicalTrials.gov | Open NCT05931367 ↗ |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 / Eli Lilly and Company | CompletedVerified 2025-11 | Phase 2146 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 1, 2025actual | Nov 25, 2025ClinicalTrials.gov | Open NCT05936151 ↗ |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 / Eli Lilly and Company | CompletedVerified 2026-03 | Phase 3537 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 22, 2026actual | Mar 5, 2026ClinicalTrials.gov | Open NCT06354660 ↗ |
| A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906NCT05296733 / Boehringer Ingelheim | CompletedVerified 2024-08 | Phase 182 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 29, 2023actual | Aug 15, 2024ClinicalTrials.gov | Open NCT05296733 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 / SYNCHRONIZE™-1 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 3726 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 2, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06066515 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 / SYNCHRONIZE™-2 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 3755 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 12, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06066528 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055 / Viking Therapeutics, Inc. | CompletedVerified 2025-09 | Phase 2280 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 24, 2025actual | Oct 6, 2025ClinicalTrials.gov | Open NCT06828055 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →